文献速递泌尿男性生殖肿瘤

转移性去势敏感性前列腺癌系统治疗比较:系统评价与网络Meta分析

Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
PubMed 文献 · JAMA Oncol · 2021-01-01

该网络Meta分析纳入7项随机临床试验共7287例mCSPC患者,比较6种系统治疗联合ADT的疗效与安全性。结果显示,阿比特龙、阿帕他胺和多西他赛联合ADT可改善总生存,恩扎卢胺、阿帕他胺、阿比特龙和多西他赛可改善影像学无进展生存;多西他赛严重不良事件风险显著增加。

要点

  • 阿比特龙联合ADT的总生存获益最大(HR 0.61),其次为阿帕他胺(HR 0.67)和多西他赛(HR 0.79)。
  • 恩扎卢胺对影像学无进展生存改善最显著(HR 0.39),但总生存获益需更长随访。
  • 多西他赛严重不良事件风险显著增高(OR 23.72),阿比特龙轻度增高(OR 1.42)。

核心结论

  • 在mCSPC中,阿比特龙和阿帕他胺联合ADT可能提供最大的总生存获益且严重不良事件风险相对较低。
  • 恩扎卢胺可能最大程度改善影像学无进展生存,但其总生存获益需更长随访验证。

研究设计与样本

  • 系统评价与贝叶斯网络Meta分析,纳入7项随机临床试验共7287例mCSPC患者,比较6种治疗联合ADT。

主要发现

  • 总生存改善:阿比特龙(HR 0.61;95%CI 0.54-0.70)、阿帕他胺(HR 0.67;95%CI 0.51-0.89)、多西他赛(HR 0.79;95%CI 0.71-0.89)。
  • 影像学无进展生存改善:恩扎卢胺(HR 0.39;95%CI 0.30-0.50)、阿帕他胺(HR 0.48;95%CI 0.39-0.60)、阿比特龙(HR 0.51;95%CI 0.45-0.58)、多西他赛(HR 0.67;95%CI 0.60-0.74)。
  • 严重不良事件:多西他赛显著增加(OR 23.72;95%CI 13.37-45.15),阿比特龙轻度增加(OR 1.42;95%CI 1.10-1.83),其他治疗无显著增加。

临床怎么用

  • 对mCSPC患者,阿比特龙或阿帕他胺联合ADT可作为优先考虑的强化治疗方案,兼顾生存获益与安全性。
  • 恩扎卢胺联合ADT在影像学无进展生存方面表现突出,但需权衡总生存证据的成熟度。
  • 多西他赛联合ADT虽有效,但严重不良事件风险高,选择时需谨慎评估患者耐受性。

局限性

  • 4项开放标签试验存在偏倚风险,3项试验有缺失数据,2项试验可能存在未预设分析。
  • 恩扎卢胺的总生存数据尚不成熟,需要更长随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Multiple systemic treatments are available for metastatic castration-sensitive prostate cancer (mCSPC), with unclear comparative effectiveness and safety and widely varied costs. OBJECTIVE: To compare the effectiveness and safety determined in randomized clinical trials of systemic treatments for mCSPC. DATA SOURCES: Bibliographic databases (MEDLINE, Embase, and Cochrane Central), regulatory documents (US Food and Drug Administration and European Medicines Agency), and trial registries (ClinicalTrials.gov and European Union clinical trials register) were searched from inception through November 5, 2019. STUDY SELECTION, DATA EXTRACTION, AND SYNTHESIS: Eligible studies were randomized clinical trials evaluating the addition of docetaxel, abiraterone acetate, apalutamide, or enzalutamide to androgen-deprivation therapy (ADT) for treatment of mCSPC. Two investigators independently performed screening. Discrepancies were resolved through consensus. A Cochrane risk-of-bias tool was used to assess trial quality. Relative effects of competing treatments were assessed by bayesian network meta-analysis and survival models. The Preferred Reporting Items for Systematic Reviews and Meta-analyses guideline was used. MAIN OUTCOMES AND MEASURES: Overall survival, radiographic progression-free survival, and serious adverse events (SAEs). RESULTS: Seven trials with 7287 patients comparing 6 treatments (abiraterone acetate, apalutamide, docetaxel, enzalutamide, standard nonsteroidal antiandrogen, and placebo/no treatment) were identified. Ordered from the most to the least effective determined by results of clinical trials, treatments associated with improved overall survival when added to ADT included abiraterone acetate (hazard ratio [HR], 0.61; 95% credible interval [CI], 0.54-0.70), apalutamide (HR, 0.67; 95% CI, 0.51-0.89), and docetaxel (HR, 0.79; 95% CI, 0.71-0.89); treatments associated with improved radiographic progression-free survival when added to ADT included enzalutamide (HR, 0.39; 95% CI, 0.30-0.50), apalutamide (HR, 0.48; 95% CI, 0.39-0.60), abiraterone acetate (HR, 0.51; 95% CI, 0.45-0.58), and docetaxel (HR, 0.67; 95% CI 0.60-0.74). Docetaxel was associated with substantially increased SAEs (odds ratio, 23.72; 95% CI, 13.37-45.15), abiraterone acetate with slightly increased SAEs (odds ratio, 1.42; 95% CI, 1.10-1.83), and other treatments with no significant increase in SAEs. Risk of bias was noted for 4 trials with open-label design, 3 trials with missing data, and 2 trials with potential unprespecified analyses. CONCLUSIONS AND RELEVANCE: In this network meta-analysis, as add-on treatments to ADT, abiraterone acetate and apalutamide may provide the largest overall survival benefits with relatively low SAE risks. Although enzalutamide may improve radiographic progression-free survival to the greatest extent, longer follow-up is needed to examine the overall survival benefits associated with enzalutamide.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Wang L, Paller CJ, Hong H, et al. Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2021. PMID: 33443584. doi:10.1001/jamaoncol.2020.6973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。